Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


Development of a novel class of glucose transporter inhibitors.

Wang D, Chu PC, Yang CN, Yan R, Chuang YC, Kulp SK, Chen CS.

J Med Chem. 2012 Apr 26;55(8):3827-36. doi: 10.1021/jm300015m. Epub 2012 Apr 10.


Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

Yang J, Wei S, Wang DS, Wang YC, Kulp SK, Chen CS.

J Med Chem. 2008 Apr 10;51(7):2100-7. doi: 10.1021/jm701212m. Epub 2008 Mar 13.


Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.

Ihle NT, Lemos R, Schwartz D, Oh J, Halter RJ, Wipf P, Kirkpatrick L, Powis G.

Mol Cancer Ther. 2009 Jan;8(1):94-100. doi: 10.1158/1535-7163.MCT-08-0714.


Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells.

Yang CC, Ku CY, Wei S, Shiau CW, Chen CS, Pinzone JJ, Ringel MD, Chen CS.

Mol Pharmacol. 2006 May;69(5):1564-70. Epub 2006 Feb 1.


Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.

Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS.

Cancer Res. 2005 Feb 15;65(4):1561-9.


Development of small-molecule cyclin D1-ablative agents.

Huang JW, Shiau CW, Yang J, Wang DS, Chiu HC, Chen CY, Chen CS.

J Med Chem. 2006 Jul 27;49(15):4684-9.


The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.

Kim SL, Kim EM, Cheong SJ, Lee CM, Kim DW, Jeong HJ, Lim ST, Sohn MH, Yim CY.

Nucl Med Biol. 2009 May;36(4):427-33. doi: 10.1016/j.nucmedbio.2009.01.010. Epub 2009 Mar 26.


Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.

Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, Shapiro CL, Chen CS.

Mol Pharmacol. 2005 Apr;67(4):1342-8. Epub 2005 Jan 13.


A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death.

Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, Klip A, Batey RA, Schimmer AD.

Mol Cancer Ther. 2008 Nov;7(11):3546-55. doi: 10.1158/1535-7163.MCT-08-0569.


Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.

Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS.

Endocr Relat Cancer. 2006 Jun;13(2):401-13. Review.


Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.

Hidalgo-Figueroa S, Ramírez-Espinosa JJ, Estrada-Soto S, Almanza-Pérez JC, Román-Ramos R, Alarcón-Aguilar FJ, Hernández-Rosado JV, Moreno-Díaz H, Díaz-Coutiño D, Navarrete-Vázquez G.

Chem Biol Drug Des. 2013 Apr;81(4):474-83. doi: 10.1111/cbdd.12102. Epub 2013 Mar 21.


Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1.

Shin SJ, Kim JY, Kwon SY, Mun KC, Cho CH, Ha E.

Eur J Pharmacol. 2014 Nov 15;743:17-23. doi: 10.1016/j.ejphar.2014.09.013. Epub 2014 Sep 21.


Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats.

García-Bueno B, Caso JR, Pérez-Nievas BG, Lorenzo P, Leza JC.

Neuropsychopharmacology. 2007 Jun;32(6):1251-60. Epub 2006 Nov 22.


Energy restriction as an antitumor target of thiazolidinediones.

Wei S, Kulp SK, Chen CS.

J Biol Chem. 2010 Mar 26;285(13):9780-91. doi: 10.1074/jbc.M109.065466. Epub 2010 Jan 21.


Methyl 6-Amino-6-deoxy-d-pyranoside-Conjugated Platinum(II) Complexes for Glucose Transporter (GLUT)-Mediated Tumor Targeting: Synthesis, Cytotoxicity, and Cellular Uptake Mechanism.

Li T, Gao X, Yang L, Shi Y, Gao Q.

ChemMedChem. 2016 May 19;11(10):1069-77. doi: 10.1002/cmdc.201600079. Epub 2016 May 2.


The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.

Cheong SJ, Lee CM, Kim EM, Lim ST, Sohn MH, Jeong HJ.

Nucl Med Biol. 2015 Feb;42(2):85-91. doi: 10.1016/j.nucmedbio.2014.08.013. Epub 2014 Sep 6.


Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin.

Mrówka P, Glodkowska E, Nowis D, Legat M, Issat T, Makowski M, Szokalska A, Janowska S, Stoklosa T, Jakóbisiak M, Golab J.

Int J Oncol. 2008 Jan;32(1):249-55.


Supplemental Content

Support Center